Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 19,384 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Efficacy Clear all
Recruiting Phase 2 Interventional

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

NCT07837973
View directory record Official record
Conditions
Overweight , Obesity, Adults
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Tempe, Arizona • Oceanside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

NCT00600483
View directory record Official record
Conditions
Cardiac Surgery, Sternal Wound Infection
Interventions
gentamicin-collagen sponge dipped in saline
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
1,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • Florence, Alabama • Pasadena, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 4, 2026, 2:28 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

NCT06381141
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CLN-619
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 4, 2026, 2:28 AM EDT
Active, not recruiting Phase 2 Interventional

Allogeneic BM-MSCs in Patients With Painful Lumbar Facet Arthropathy

NCT06001853
View directory record Official record
Conditions
Facet-Mediated Low Back Pain, Lumbar Facet Joint Osteoarthritis
Interventions
BM-MSC injection, DSMO Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Bay98-7196, Dose Finding / POC Study

NCT02203331
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 4, 2026, 2:28 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402
View directory record Official record
Conditions
Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
Interventions
Barzolvolimab, Matching Placebo
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

NCT02577523
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ND0612 (Levodopa/Carbidopa solution), ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Farmington Hills, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

NCT02356588
View directory record Official record
Conditions
Post-Operative Pain
Interventions
Sufentanil Tablet 30 mcg, Placebo Tablet
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
4
States / cities
Sheffield, Alabama • Pasadena, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 4, 2026, 2:28 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

NCT00449761
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Duarte, California • Aurora, Colorado • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

NCT01336569
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004%/timolol maleate 0.5% fixed combination
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Oct 4, 2026, 2:28 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia

NCT04882969
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Fractionated Thulium laser
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT05364554
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Sacramento, California • Ocala, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 4, 2026, 2:28 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

NCT03715153
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
2 Years to 6 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 4, 2026, 2:28 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00474188
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
CC-5013 (lenalidomide), dexamethasone
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Glendale, Arizona • Beverly Hills, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

NCT03925727
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye
Interventions
Tavilermide ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers

NCT00764361
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
doxycycline, placebo gel
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

NCT02842242
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic Obstructive, Left Ventricular Outflow Tract Obstruction
Interventions
MYK-461
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)

NCT04020341
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
1,531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

NCT02938494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-123 Lotion, Tazorac Cream, Vehicle Lotion, Vehicle Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Encinitas, California • Fremont, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 2 Interventional

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

NCT04923594
View directory record Official record
Conditions
Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
Interventions
mazindol extended release, Placebo
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

NCT03830866
View directory record Official record
Conditions
Locally Advanced Cervical Cancer
Interventions
Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
Biological · Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 4, 2026, 2:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

NCT02178722
View directory record Official record
Conditions
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC)
Interventions
MK-3475, INCB024360
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
24
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 4, 2026, 2:28 AM EDT